Publications

HRA Pharma has collaborated on a number of scientific publications in the areas of women’s health and endocrinology – whether through scientific cooperation or sponsorship.

filter by theme
Women's health
Endocrinology
Academic support
Non clinical
 contact us

Publications

HRA Pharma has collaborated on a number of scientific publications in the areas of women’s health and endocrinology – whether through scientific cooperation or sponsorship.

Effects of the progesterone receptor modulator VA2914 in a continuous low dose on the hypothalamic-pituitary-ovarian axis and endometrium in normal women: a prospective, randomized, placebo-controlled trial.
Chabbert-Buffet N, Pintiaux-Kairis A, Bouchard P; VA2914 Study Group. J Clin Endocrinol Metab. 2007;92(9):3582-9.
Progesterone receptor modulator CDB-2914 down-regulates vascular endothelial growth factor, adrenomedullin and their receptors and modulates progesterone receptor content in cultured human uterine leiomyoma cells.
Xu Q, Ohara N, Chen W, Liu J, Sasaki H, Morikawa A, Sitruk-Ware R, Johansson ED, Maruo T. Hum Reprod. 2006;21(9):2408-16.
Nallasamy S, Kim J, Sitruk-Ware R, Bagchi M, Bagchi I. Ulipristal blocks ovulation by inhibiting progesterone receptor-dependent pathways intrinsic to the ovary.
Reprod Sci 2013 Apr; 20:371-381
Palinasamy GS, Cheon Y-P, Kim J, et al. A novel pathway involving progesterone receptor, endothelin-2, and endothelin receptor B controls ovulation in mice. Mol
Endocrinol 2006; 20: 2784-2795
Pohl O, Williams AR, Bergeron C, Gotteland JP. A 39-week oral toxicity study of ulipristal acetate in cynomolgus monkeys.
Regul Toxicol Pharmacol. 2013 a;66:6-12
Pohl O, Harvey PW, McKeag S, Boley SE, Gotteland JP. Carcinogenicity and chronic rodent toxicity of the selective progesterone receptor modulator ulipristal acetate.
Curr Drug Saf. 2013 b; 8:77-97.
Liposomal polychemotherapy improves adrenocortical carcinoma treatment in a preclinical rodent model.
Hantel C, Jung S, Mussack T, Reincke M, Beuschlein F. Endocr Relat Cancer. 2014 Feb 14.
Lack of long-lasting effects of mitotane adjuvant therapy in a mouse xenograft model of adrenocortical carcinoma.
Doghman M, Lalli E. Mol Cell Endocrinol. 2013 Dec 5;381(1-2):66-9.
closeyou are leaving hra pharma
You are now leaving www.hra-pharma.com and being redirected to an external website which might not be under control of HRA Pharma.
do you want to proceed ?